Is Cytoreductive Nephrectomy Still Beneficial for Patients With Metastatic Renal Cell Carcinoma in the Contemporary Immunotherapy Era?

다국어 초록 (Multilingual Abstract)

Cytoreductive nephrectomy (CN) has long been the standard of care for patients with metastatic renal cell carcinoma (mRCC) since 2 clinical trials revealed its role during the cytokines era. With discovery of novel and effective drugs, such as vascular endothelial growth factor-targeted therapies, the role of CN started to be challenged. The 2 recent prospective randomized trials Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques (CARMENA) and Immediate Surgery or Surgery After Sunitinib in Treating Patients with Metastatic Kidney Cancer trial (SURTIME) have changed the therapy paradigm for patients with mRCC. The CARMENA trial was performed to reveal whether CN is required in the targeted therapy, whereas SURTIME evaluated whether initial sunitinib can aid in the selection of patients who are most likely to benefit from subsequent CN or identify patients with innate resistance to targeted therapy. These trials suggest that CN does not provide a survival benefit for patients with poor‑risk disease. Especially, current evolutions in systemic therapies have demonstrated improved oncological outcomes from immunotherapy (IO) such as immune checkpoint inhibitor, particularly in its combination or combination with tyrosine kinase inhibitor. Accordingly, the role of CN continues to be questioned. Taken together, these findings reinforce the concept that the ultimate impact of CN on oncologic outcomes of mRCC patients in the era of IO still needs further investigation to represent a key for unmet clinical need.

참고문헌 (Reference)

1 Woldu SL, "What is the role of nephrectomy following complete response to checkpoint inhibitors?" 18 : 60-63, 2018

2 Bex A, "Updated European Association of Urology Guidelines for cytoreductive nephrectomy in patients with synchronous metastatic clear-cell renal cell carcinoma" 74 : 805-, 2018

3 Jiang T, "Tumor neoantigens : from basic research to clinical applications" 12 : 93-, 2019

4 Saad AM, "Trends in renal‑cell carcinoma incidence and mortality in the United States in the last 2 decades : a SEER‑based study" 17 : 46-, 2019

5 Stoecklein VM, "Trauma equals danger : damage control by the immune system" 92 : 539-551, 2012

6 Choueiri TK, "The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy" 185 : 60-66, 2011

7 Graham J, "The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma" 29 : 507-512, 2019

8 Hudes G, "Temsirolimus, interferon alfa, or both for advanced renal‑cell carcinoma" 356 : 2271-, 2007

9 Choueiri TK, "Systemic therapy for metastatic renal‑cell carcinoma" 376 : 354-, 2017

10 De Bruijn RE, "Surgical safety of cytoreductive nephrectomy following sunitinib : results from multicentre, randomised controlled trial of immediate versus deferred nephrectomy(SURTIME)" 7 : 437-440, 2019

11 Motzer RJ, "Sunitinib versus interferon alfa in metastatic renal‑cell carcinoma" 356 : 115-, 2007

12 Méjean A, "Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma" 379 : 417-427, 2018

13 Escudier B, "Sorafenib in advanced clear‑cell renal‑cell carcinoma" 356 : 125-, 2007

14 Massari F, "Should CARMENA really change our attitude towards cytoreductive nephrectomy in metastatic renal cell carcinoma? A systematic review and meta-analysis evaluating cytoreductive nephrectomy in the era of targeted therapy" 13 : 705-, 2018

15 Fujikawa K, "Serum C‑reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma" 162 : 1934-, 1999

16 Guinan P, "Report of 337 patients with renal cell carcinoma emphasizing 110 with stage IV disease and review of the literature" 64 : 295-, 1997

17 Garfield DH, "Regression of metastatic renal cell carcinoma following nephrectomy" 30 : 190-, 1972

18 Marcus SG, "Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy" 150 : 463-, 1993

19 Mickisch GH, "Radical nephrectomy plus interferon–alfa–based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial" 358 : 966-970, 2001

20 Lahn M, "Pro‑inflammatory and T cell inhibitory cytokines are secreted at high levels in tumor cell cultures of human renal cell carcinoma" 35 : 70-, 1999

21 Motzer RJ, "Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma" 22 : 454-463, 2004

22 Robertson CN, "Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells" 144 : 614-, 1990

23 Rini BI, "Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma : final results of CALGB 90206" 28 : 2137-2143, 2010

24 Rini BI, "Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma" 380 : 1116-1127, 2019

25 Motzer RJ, "Pazopanib versus sunitinib in metastatic renal-cell carcinoma" 369 : 722-731, 2013

26 Shapiro DD, "Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint inhibitors" 29 : 513-520, 2019

27 Motzer RJ, "Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma" 27 : 3584-3590, 2009

28 Motzer RJ, "Nivolumab plus ipilimumab versus sunitinib in advanced renalcell carcinoma" 378 : 1277-1290, 2018

29 Mathieu R, "Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features" 33 : 339-, 2015

30 Flanigan RC, "Nephrectomy followed by interferon alfa‑2b compared with interferon alfa‑2b alone for metastatic renal‑cell cancer" 345 : 1655-, 2001

31 Fallick ML, "Nephrectomy before interleukin-2therapy for patients with metastatic renal cell carcinoma" 158 : 1691-1695, 1997

32 Pantuck AJ, "Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma" 345 : 1711-1712, 2001

33 Bex A, "Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability : initial experience with downsizing to reconsider cytoreductive surgery" 27 : 533-, 2009

34 Motzer RJ, "NCCN guidelines insights:kidney cancer, version 2.2020" 17 : 1278-, 2019

35 Finke JH, "Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics" 19 : 353-364, 2013

36 de Riese W, "Metastatic renal cell carcinoma(RCC) : spontaneous regression, longterm survival and late recurrence" 23 : 13-25, 1991

37 Verra N, "Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy" 48 : 527-, 2005

38 Larcher A, "Individualised indications for cytoreductive nephrectomy : which criteria define the optimal candidates?" 4 : 365-378, 2019

39 Singla N, "Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era : an analysis of the National Cancer Database" 38 : 604-, 2020

40 Gore ME, "Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma" 113 : 12-19, 2015

41 Rouprêt M, "European Association of Urology Guidelines on upper urinary tract urothelial carcinoma : 2020 update" 79 : 62-79, 2021

42 Marchioni M, "Development of a novel risk score to select the optimal candidate for cytoreductive nephrectomy among patients with metastatic renal cell carcinoma. Results from a Multiinstitutional Registry (REMARCC)" 4 : 256-263, 2021

43 "Deferred CytoreductiveNephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial (NORDIC-SUN)" ClinicalTrials.gov

44 Franklin JR, "Cytoreductive surgery in the management of metastatic renal cell carcinoma : the UCLA experience" 14 : 230-, 1996

45 Bennett RT, "Cytoreductive surgery for stage IV renal cell carcinoma" 154 : 32-34, 1995

46 Mejean A, "Cytoreductive nephrectomy(CN)in metastatic renal cancer(mRCC) : update on Carmena trial with focus on intermediate IMDC-risk population" 37 (37): 4508-, 2019

47 Heng DY, "Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma : results from the International Metastatic Renal Cell Carcinoma Database Consortium" 66 : 704-710, 2014

48 Flanigan RC, "Cytoreductive nephrectomy in patients with metastatic renal cancer : a combined analysis" 171 : 1071-, 2004

49 Tabakin AL, "Cytoreductive nephrectomy for metastatic renal cell carcinoma, the ultimate urologic"Chosing Wisely"campaign : a narrative review" 9 : 7337-7349, 2020

50 Bex A, "Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib : the SURTIME randomized clinical trial" 5 : 164-170, 2019

51 Konishi S, "Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma : a real-world multicenter analysis" 36 : 6-, 2018

52 "Comparing the outcome of immunotherapy-based drug combination therapy with or without surgery to remove the kidney in metastatic kidney cancer, the PROBE trial (PROBE)" ClinicalTrials.gov

53 Bakos O, "Combining surgery and immunotherapy : turning an immunosuppressive effect into a therapeutic opportunity" 6 : 86-, 2018

54 Culp SH, "Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?" 116 : 3378-3388, 2010

55 Choueiri TK, "Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk(Alliance A031203 CABOSUN randomised trial) : Progressionfree survival by independent review and overall survival update" 94 : 115-125, 2018

56 Motzer RJ, "Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma" 380 : 1103-1115, 2019

57 Warren M, "A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment" 3 : 281-289, 2009